• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Jami Rubin Announced as Boundless Bio Chief Financial Officer


New executive brings over 30 years of experience in the biopharma industry.

A medical cost, big pharma concept with a glass of water, various medicine, US dollar bills and the American flag. Image Credit: Adobe Stock Images/Ming

Image Credit: Adobe Stock Images/Ming

Boundless Bio, a biopharma company based out of San Diego, has announced the appointment of Jami Rubin as chief financial officer. Prior to joining the organization, Ms. Rubin was most recently employed as chief financial officer at EQRx. Other experiences include leading the healthcare business unit at Goldman Sachs and serving as a partner at PJT Partners.

“Jami is a distinguished life sciences industry leader, and we are thrilled to welcome her to Boundless Bio,” said Zachary Hornby, President, CEO, Boundless Bio, in a company press release. “With our lead ecDNA-directed therapy, BBI-355, now in clinical development, Jami’s significant business acumen, operational expertise, and deep industry experience will help propel Boundless Bio as we enter our next phase of growth and seek to deliver potentially transformative new therapies to the more than 400,000 patients newly diagnosed in the US each year with previously intractable oncogene amplified cancers.”

Reference: Boundless Bio Appoints Jami Rubin as Chief Financial Officer. Business Wire. July 31, 2023. Accessed July 31, 2023. https://www.businesswire.com/news/home/20230728676039/en/Boundless-Bio-Appoints-Jami-Rubin-as-Chief-Financial-Officer

Related Content